Newron Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Newron Pharmaceuticals has been growing earnings at an average annual rate of 4.4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 10.4% per year.
Key information
4.4%
Earnings growth rate
4.4%
EPS growth rate
Pharmaceuticals Industry Growth | 16.3% |
Revenue growth rate | 10.4% |
Return on equity | n/a |
Net Margin | -179.1% |
Next Earnings Update | 19 Sep 2024 |
Recent past performance updates
Recent updates
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Nov 06Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package
Apr 06Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?
Apr 01A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns
Feb 25Revenue & Expenses BreakdownBeta
How Newron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 9 | -16 | 8 | 13 |
30 Sep 23 | 9 | -16 | 8 | 13 |
30 Jun 23 | 9 | -16 | 8 | 12 |
31 Mar 23 | 7 | -17 | 7 | 12 |
31 Dec 22 | 6 | -17 | 7 | 12 |
30 Sep 22 | 6 | -16 | 7 | 11 |
30 Jun 22 | 6 | -14 | 7 | 10 |
31 Mar 22 | 6 | -15 | 7 | 10 |
31 Dec 21 | 6 | -15 | 7 | 11 |
30 Sep 21 | 6 | -17 | 8 | 12 |
30 Jun 21 | 5 | -20 | 8 | 14 |
31 Mar 21 | 5 | -20 | 8 | 14 |
31 Dec 20 | 5 | -21 | 8 | 15 |
30 Sep 20 | 6 | -19 | 9 | 15 |
30 Jun 20 | 7 | -17 | 9 | 15 |
31 Mar 20 | 7 | -18 | 10 | 16 |
31 Dec 19 | 7 | -20 | 10 | 17 |
30 Sep 19 | 6 | -21 | 11 | 16 |
30 Jun 19 | 4 | -21 | 11 | 15 |
31 Mar 19 | 4 | -18 | 10 | 12 |
31 Dec 18 | 4 | -15 | 9 | 10 |
30 Sep 18 | 4 | -15 | 9 | 9 |
30 Jun 18 | 4 | -14 | 9 | 9 |
31 Mar 18 | 9 | -10 | 9 | 8 |
31 Dec 17 | 13 | -5 | 9 | 8 |
30 Sep 17 | 14 | -5 | 10 | 8 |
30 Jun 17 | 15 | -5 | 10 | 8 |
31 Mar 17 | 11 | -10 | 10 | 10 |
31 Dec 16 | 7 | -15 | 10 | 12 |
30 Sep 16 | 6 | -20 | 10 | 13 |
30 Jun 16 | 4 | -25 | 9 | 15 |
31 Mar 16 | 3 | -24 | 9 | 13 |
31 Dec 15 | 2 | -23 | 9 | 11 |
30 Sep 15 | 2 | -18 | 8 | 9 |
30 Jun 15 | 2 | -12 | 8 | 6 |
31 Mar 15 | 2 | -11 | 7 | 5 |
31 Dec 14 | 2 | -10 | 7 | 4 |
30 Sep 14 | 2 | -10 | 7 | 4 |
30 Jun 14 | 3 | -9 | 7 | 4 |
31 Mar 14 | 3 | -8 | 7 | 3 |
31 Dec 13 | 4 | -7 | 7 | 2 |
30 Sep 13 | 4 | -7 | 8 | 2 |
30 Jun 13 | 4 | -8 | 9 | 3 |
31 Mar 13 | 6 | -5 | 9 | 3 |
Quality Earnings: NWRN is currently unprofitable.
Growing Profit Margin: NWRN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NWRN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare NWRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NWRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.4%).
Return on Equity
High ROE: NWRN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.